anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is underdiagnosed with the current gold standard measure pulmonary function test (PFT). A more sensitive and simple option for early detection and severity evaluation of COPD could benefit practitioners and patients.
METHODS: In this multicenter retrospective study, frontal chest X-ray (CXR) images and related clinical information of 1055 participants were collected and processed. Different deep learning algorithms and transfer learning models were trained to classify COPD based on clinical data and CXR images from 666 subjects, and validated in internal test set based on 284 participants. External test including 105 participants was also performed to verify the generalization ability of the learning algorithms in diagnosing COPD. Meanwhile, the model was further used to evaluate disease severity of COPD by predicting different grads.
RESULTS: The Ensemble model showed an AUC of 0.969 in distinguishing COPD by simultaneously extracting fusion features of clinical parameters and CXR images in internal test, better than models that used clinical parameters (AUC = 0.963) or images (AUC = 0.946) only. For the external test set, the AUC slightly declined to 0.934 in predicting COPD based on clinical parameters and CXR images. When applying the Ensemble model to determine disease severity of COPD, the AUC reached 0.894 for three-classification and 0.852 for five-classification respectively.
CONCLUSION: The present study used DL algorithms to screen COPD and predict disease severity based on CXR imaging and clinical parameters. The models showed good performance and the approach might be an effective case-finding tool with low radiation dose for COPD diagnosis and staging.
PURPOSE: An NF-kappaB inhibitor containing ARH1 protein or gene encoding the same is provided to suppress intracellular NF-kappa B and treat inflammatory disease, autoimmune diseases, or viral diseases. CONSTITUTION: A NF-kappa B inhibitor contains an ARH1 protein or gene encoding the same as an active ingredient. The ARH1 protein suppresses nuclear translocation of p50 or p65 of NF-kappaB. The NF-kappaB inhibitor is performed by binding ARH1 protein and TRADD(TNF receptor-associated death domain). The ARH1 protein or a gene encoding the same is derived from human. A composition for treating disease relating to NF-kappa abnormal activation contains the NF-kappaB inhibitor.
PURPOSE: An inhaling type powder formulation for preventing or treating NMDA receptor function degradation related diseases is provided to effective and safe for promoting growth by identical amount of administration. CONSTITUTION: An inhaling type powder formulation for preventing or treating NMDA receptor function degradation related diseases includes growth hormone as an active component. The NMDA receptor function degradation related diseases include schizophrenia induced symptoms including dementia, Alzheimer's disease, schizophrenia, senescence related reduction of learning and memory, drug induced-NMDA receptor function degradation, NMDA antagonist-induced mental disease symptoms-or cognition disorder, Huntington`s disease or chronic alcoholism. The inhaling type powder formulation additionally includes pharmaceutically acceptable excipient. The pharmaceutically acceptable excipient includes monosaccharide such as glucose and arabinose; disaccharides such as lactose saccharose and maltose; polysaccharides such as sorbitol, mannitol and xylitol; salt such as sodium chloride and calcium carbonate; calcium bicarbonate; amino acid; peptide: polymers: lipid: or a mixture thereof. The inhaling type powder formulation includes growth hormone, lactose and dipalmitoyl phosphatidylcholine(DPPC). [Reference numerals] (AA) Relative quantification; (BB) Counter group powder; (CC) Saline solution
Up to 5 sequential dose escalation cohorts of COM701 in combination with fixed doses of BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks until a maximum tolerated dose or recommended dose for expansion is identified.
Attention deficit hyperactivity disorder (ADHD) is characterized by inattention, impulsiveness, and hyperactivity. ADHD is not commonly diagnosed until a child has entered formal schooling and shown academic and behavioral adjustment difficulties, but developmental research suggests that risk factors for developing ADHD are evident earlier. A significant number of children start school with high levels of disorganized and inattentive behaviors, which are symptoms of emerging ADHD. This study will test an intervention aimed at preventing the development of ADHD by identifying those at risk for developing ADHD in kindergarten and pre-kindergarten and teaching them self-regulation skills through socialization. These skills have been associated with school success, and they may reduce the likelihood of children developing ADHD.

Participation in this study will last for 4 months, with a follow-up assessment after 1 year. To enroll, child participants will undergo a screening process that will include assessments by their teachers and parents. Eligible child participants will also be assessed by researchers in a classroom setting. They will then be randomly assigned to receive either a play-based intervention, called the Friendship Group, or an individual pre-academic tutoring intervention. Both groups will meet at school. The Friendship Group, which will focus on strengthening attention and self-regulation through social skills, will involve 30 sessions twice a week for 15 weeks. The tutoring intervention, which will focus on strengthening academic skills, will involve one or two sessions a week for 4 months. Participants will be assessed at three time points: pre-intervention, post-intervention, and after 1 year. Assessments will include teacher ratings and direct testing of child attention, language, and pre-academic skills.
The duodenum is an important source of endocrine and paracrine signals controlling digestion and nutrient disposition, notably including the main incretin hormone glucose-dependent insulinotropic polypeptide (GIP). Bariatric procedures that prevent nutrients from contact with the duodenal mucosa are particularly effective interventions to reduce body weight and improve glycaemic control in obesity and type 2 diabetes. These procedures take advantage of increased nutrient delivery to more distal regions of the intestine which enhances secretion of the other incretin hormone glucagon-like peptide-1 (GLP-1). Preclinical experiments have shown that either an increase or a decrease in the secretion or action of GIP can decrease body weight and blood glucose in obesity and non-insulin dependent hyperglycaemia, but clinical studies involving administration of GIP have been inconclusive. However, a synthetic dual agonist peptide (tirzepatide) that exerts agonism at receptors for GIP and GLP-1 has produced marked weight-lowering and glucose-lowering effects in people with obesity and type 2 diabetes. This appears to result from chronic biased agonism in which the novel conformation of the peptide triggers enhanced signalling by the GLP-1 receptor through reduced internalisation while reducing signalling by the GIP receptor directly or via functional antagonism through increased internalisation and degradation.
In an active-controlled clinical trial, 743 women 18 to 45 years of age were studied to assess the efficacy of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets, for up to six 28-day cycles. The racial demographic of women randomized to norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets was: 69.5% Caucasian, 15.5% African-American, 10.4% Hispanic, 2.3% Asian and 2.3% Native American/Other. Women with body mass index (BMI) greater than 35 mg/m2 were excluded from the study. The weight range for those women treated was 90 to 260 pounds, with a mean weight of 147 pounds. Among the women in the study randomized to norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets, 38.9% had not used hormonal contraception immediately prior to enrolling in this study. 

A total of 583 women completed 6 cycles of treatment. There were a total of 5 on-treatment pregnancies among women aged 18 to 45 years in 3,565 treatment cycles during which no back-up contraception was used. The Pearl Index for norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets was 1.82 (95% confidence interval 0.59 to 4.25).
The patent discloses a traditional Chinese medicine composition for reducing blood sugar, a preparation method and application thereof. The active ingredients of the traditional Chinese medicine composition for reducing blood sugar are as follows: 20-30 parts of mulberry leaf, 10-20 parts of balsam pear, 10-20 parts of kudzu root and a group B: 5 to 15 weight parts of Chinese yam is prepared by extracting with 70 to 30 percent alcohol-water solution or/and water in a gradient way. Adding pharmaceutically acceptable adjuvants, and making into oral preparation such as oral liquid, granule, tablet, hard capsule, soft capsule, pill, etc. by conventional method. The pharmacodynamic test result shows that: the hypoglycemic traditional Chinese medicine composition can obviously reduce the blood sugar of type 2 diabetes experimental rats, saccharify hemoglobin (GHb), improve oxidative stress indexes, and has the obvious functions of regulating blood fat, increasing HDL-C, and reducing TC, TG and LDL-C. The active components of the Chinese medicinal composition can be mixed with rice and flour to make health food for preventing and treating diabetes such as porridge, noodle, bread, biscuit, etc.
The purpose of this study is to study the efficacy of a remote range of motion monitor, the Knee Glider, alongside a patient engagement platform, Force Therapeutics, on clinical improvements and cost following primary TKA. Patients will be given the opportunity to participate, and enrolled and consented participants will be treated and followed by physicians from OSI Orthopedic \& Sports Medicine. Upon consent, patients will be randomized to receive the active range of motion monitor (the knee glider) two weeks prior to surgery, near day of surgery to use postoperatively, or standard of care (no knee glider). All patients enrolled in the study will have access to Force Therapeutics, patient engagement and outcome collection system utilized by OSI Orthopedic \& Sports Medicine. Enrolled subjects will be followed from the time of consent, through 6 months following surgery. Patients who are randomized into groups receiving the knee glider will receive the knee glider for up to 4 weeks following surgery, and compliance will be monitored. The hypothesis of this study is that patients who utilize an active range of motion monitor (the knee glider) will have improved clinical outcomes over patients receiving standard of care.
This clinical study is a multicenter open-label study on the adult and pediatric hematopoietic stem cell transplantation (HSCT) patients. The primary objective is to confirm the preventive efficacy for herpes simplex virus (HSV) infection of 256U87 (VACV: valaciclovir) due to the treatment before or immediately after hematopoietic stem cell transplantation. The secondary objective is to confirm the safety of VACV in the case of its use for such a purpose.

This clinical study consists of the following two periods: the screening period lasting 7 days at the longest and the administration period from 7 days before HSCT to 35 days after HSCT (43 days in total). During the administration period, adult patients are orally given a VACV tablet twice daily, while pediatric patients are orally given VACV granules twice daily at a dose of 25 mg/kg b.w. (maximum dose per treatment: 500 mg). Pediatric patients weighing 40 kg or over may be orally given a VACV tablet twice daily.
Once enrolled, participants will complete a baseline sampling session and then three sequences of study product administration, along with sRAI and administration of autologous seminal fluid. Sequence A will be 1 TFV douche followed by sRAI; Sequence B will be one dose of TFV douche followed sRAI then a tap water douche; Sequence C will be 1 tap water douche followed sRAI then by a single dose of TFV douche. There will be a washout period of at least 14 days between sequences. Participants will have sequences administered in clinic or a research unit, followed by imaging and various specimen collections over 8 hours.
In order to derive the most effective pressure, CPAP titration is performed in the sleep laboratory during which the pressure is gradually increased until apneas and hypopneas are abolished in all sleep stages and in all body positions. The technique is however time consuming and labor intensive. Furthermore, the duration of the study may not be sufficient to attain this goal because of patient's poor ability to sleep in this environment or due to difficulty in attaining an appropriate pressure. A predictive algorithm based on demographic, anthropometric, and polysomnographic data was developed to facilitate the selection of a starting pressure during the overnight titration study. Yet, the performance of this model was inconsistent when validated by other centers. One of the potential reasons for the lack of reproducibility is the complex relation of behavioral processes with nonlinear attributes. In areas of complex interactions, the artificial neural network (ANN) has been found to be a more appropriate alternative to linear, parametric statistical tools due to its inherent property of seeking information embedded in relations among variables thought to be independent.

Comparison: time to achieve optimal pressure in the conventional technique versus the intervention model
During mechanical ventilation the lungs can be inflated with different pressure and flow waveforms. Originally the piston-driven mechanical ventilators generated a quasi-sinusoidal flow waveform, whereas the newer electronically controlled ventilators can also produce constant and decelerating waveforms. According to several theoretical,animal and clinical studies,the inspiratory flow waveform affects the distribution of the inspired gas as well as respiratory mechanics and gas exchange. However, other studies failed to show any significant effect.But there is no study interested to the effects of inspiratory flow waveforms on cardiac preload. Thus, the clinical usefulness of inspiratory flow pattern manipulation remains unclear, though the capacity for selection of different inspiratory flow waveforms is provided by most modern, microprocessor-equipped ventilators. Therefore, the purpose of this study was to compare the effects of flow patterns (sinusoidal, constant and decelerating) on dynamic measurements of cardiac preload dependence such as arterial pulse pressure variation (ΔPP) and distensibility index of the inferior vena cava (dIVC).
OXYGEN, COMPRESSED USP UN1072 PRODUCED BY AIR LIQUIFACTION OXYGEN 2   
WARNING: For emergency use only when administered by properly trained personnel for oxygen deficiency and resuscitation. For all other medical application, Rx only. Uninterrupted use of high concentrations of oxygen over a long duration, without monitoring its effect on oxygen content of arterial blood, may be harmful. Do not attempt to use on patients who have stopped breathing unless used in conjunction with resuscitative equipment. Keep out of reach of children. Federal law requires that this container be refilled with oxygen USP only by establishments registered as a drug manufacturer in accordance with the Federal Food, Drug and Cosmetic Act. DANGER: MAY CAUSE OR INTENCIFY FIRE; OXYDIZER. CONTAINS GAS UNDER PRESSURE; MAY EXPLODE IF HEATED. Do not handle until all safety precautions have been read and understood. Keep and store away from clothing and other combustible materials. Keep valves and fittings free from grease and oil. Use and store only outdoors or in a well-ventilated place. In case of fire; Stop leak if safe to do so. Use a back flow preventive device in the piping. Use only with equipment of compatible materials of construction and rated for cylinder pressure. Use only with equipment cleaned for oxygen service. Open valve slowly. Close valve after each use and when empty. Protect from sunlight when ambient temperature exceeds 52 C (125 F). Read and follow the Safety Data Sheet (SDS) before use.   
CAS: 7782-44-7 DO NOT REMOVE THIS PRODUCT LABEL   
HUMPHRIES 34 EAST MAIN AMERICAN FORK, UT 84003 (801) 756-3566 

Revised: 10/2024

Document Id: 25c93d2a-3c49-ca3a-e063-6294a90a312e

34391-3

Set id: 34464007-7880-454a-9f8f-b9fb5621c47b

Version: 11

Effective Time: 20241031

Humphries, Inc.
PURPOSE:To obtain an antigen liquid which can be preserved stably for a long time with a synergic effect with pH, by controlling a rubella HA antigen liquid above the characteristic pH to stabilize while sodium azide is added to prevent contamination by microorganism. CONSTITUTION:The culture of kidney cell of a young hamster is vacinated with rubella virus and after several days, the cultured liquid is subjected to a treatment or the like to obtain a rubella HA angiten liquid. The antigen liquid is controlled above pH 9.6 by NaOH to stabilize the preserved freeze dry for re-using. While the antigen liquid is controlled above pH 9.6, sidium azide is added thereto to reach the concentration of 0.05-10% (W/V) to enable preservation thereof for a long time without lowering the valance thereof. Moreover, the longer time stable preservation is made possible by freezing it dry. Thus, the anti-virus antibody valence is measured accurately with a better reproducibility by a red blood corpuscle agglutination control test using the HA antigen thereby facilitating the diagnosis of the contagion of rubella and existing contagion.
FIELD: medicine, stomatology. SUBSTANCE: medicinal film has the following components, weight %: ultrahighly dispersed hydroxyapatite 10-40; antibacterial agents 0-5; antioxidants 0-0.5, and polymeric base - the rest. Antibacterial agents and/or antioxidants and hydroxyapatite were placed by layers being hydroxyapatite layer is applied after antibacterial agent and /or antioxidants. The proposed agent can be used for treatment of surgery treatment of parodontium inflammatory disease. EFFECT: enhanced effectiveness of treatment. 2 cl
Intervention is insertion intra-operatively of conventional, non-impregnated catheters. There are two sizes to accommodate children in different size ranges: Cook Incorporated Double Lumen Polyurethane Central Venous Catheters, 4 Fr., 8 cm long, (C-UDLM-401J), 5 Fr., 8 cm long, (C-UDLM-501J), and 5 Fr., 12 cm long (C-UDLM-501J-RSC).
Nitisinone is an inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase, an enzyme in the tyrosine metabolic pathway [see Clinical Pharmacology (12.1)]. Therefore, treatment with ORFADIN may cause an increase in plasma tyrosine levels in patients with HT-1. Maintain concomitant reduction in dietary tyrosine and phenylalanine while on ORFADIN treatment. Do not adjust ORFADIN dosage in order to lower the plasma tyrosine concentration. Maintain plasma tyrosine levels below 500 micromol/L. Inadequate restriction of tyrosine and phenylalanine intake can lead to elevations in plasma tyrosine levels and levels greater than 500 micromol/L may lead to the following: 

  * Ocular signs and symptoms including corneal ulcers, corneal opacities, keratitis, conjunctivitis, eye pain, and photophobia have been reported in patients treated with ORFADIN [see Adverse Reactions (6.1)]. In a clinical study in a non HT-1 population without dietary restriction and reported tyrosine levels >500 micromol/L both symptomatic and asymptomatic keratopathies have been observed. Therefore, perform a baseline ophthalmologic examination including slit-lamp examination prior to initiating ORFADIN treatment and regularly thereafter. Patients who develop photophobia, eye pain, or signs of inflammation such as redness, swelling, or burning of the eyes or tyrosine levels are > 500 micromol/L during treatment with ORFADIN should undergo slit-lamp reexamination and immediate measurement of the plasma tyrosine concentration. 
  * Variable degrees of intellectual disability and developmental delay. In patients treated with ORFADIN who exhibit an abrupt change in neurologic status, perform a clinical laboratory assessment including plasma tyrosine levels. 
  * Painful hyperkeratotic plaques on the soles and palms 



In patients with HT-1 treated with dietary restrictions and ORFADIN who develop elevated plasma tyrosine levels, assess dietary tyrosine and phenylalanine intake.
Patients in this arm will receive 15-25 gentle strokes of dry needling (piercing of the tendon) at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises. No blood will be injected into the tendon.
PROBLEM TO BE SOLVED: To obtain a cosmetic excellent in emulsion stability, having a refreshing feeling in use free from greasiness, comprising a component containing an oil phase, a lower alcohol and water and a preferably polymer compound as an emulsifying agent or an emulsifying auxiliary. SOLUTION: This cosmetic is obtained by adding a polymer compound having orientation to a system composed of an oil phase (preferably silicone oil), a lower alcohol and water. A copolymer containing both a hydrophilic segment and a segment of an organopolysiloxane is preferable as the polymer compound. An end-blocked Nacylalkyleneimine, polyalkylene glycol, acrylic acid, etc., are preferable as hydrophilic segment. Preferably, the weight ratio of the hydrophilic segment and the segment of the organopolysiloxane is 1/50 to 20/1 and the weight-average molecular weight of the polymer compound is 500 500,000. Preferably, the composition comprises 10-90wt.% of the oil component, 0.05-10wt.% of the polymer compound and 1-40wt.% of the lower alcohol.
The developed intervention will be delivered in a workshop format by facilitators, over 8 sessions for teens and 2 sessions for parent/guardian(s). Feedback will be elicited on delivery mode (virtual, in-person, or hybrid) during the co-development sessions. If in-person/hybrid is suggested, feedback will be elicited about preferred location (e.g., a local community center, sports club, etc.). Sessions will be hosted in either Spanish or English depending on participants' preference, using video conference tools. Parent/guardian(s) will complete a 5-minute survey pre-intervention and immediately post-intervention. Teens will complete a 15-minute survey pre-intervention, immediately after the 8 session intervention, three-month post-intervention, six-month post-intervention, and twelve-month post-intervention. Surveys will assess acceptability and risk behaviors. As in the published Cuidate trials, previously used measures will be used to document validity and comparability.